Healthcare Management Solutions

HMSBilling.com

Healthcare Management Solutions (HMS) is a Practice Management Company. We perform our services in such a way as to allow you to practice medicine the way you want to. That is to provide the best possible patient care. Many billing companies bill your patient charges and collect what they can from the insurance companies. They send statements and collect what they can from the patients. There is much more your billing company can, and should do for you.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich | October 01, 2020

news image

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More

Industrial Impact

PHENOMEX'S BEACON® TECHNOLOGY ENABLES EARLY IDENTIFICATION OF POTENT OMICRON-NEUTRALIZING ANTIBODIES

PRNewswire | June 14, 2023

news image

PhenomeX Inc. the functional cell biology company, announced that the Company's technology was recently featured in a groundbreaking study published in Cell Reports titled "Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence" that has revealed the remarkable efficacy of vaccines in generating potent antibodies against emerging variants at an accelerated rate. The study, conducted by researchers from the La J...

Read More

TARGOVAX PLANS CHECKPOINT COMBO TRIAL AFTER POSTING EARLY DATA ON ONCOLYTIC VIRUS

FierceBiotech | January 22, 2020

news image

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the ...

Read More

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

news image

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More
news image

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich | October 01, 2020

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More
news image

Industrial Impact

PHENOMEX'S BEACON® TECHNOLOGY ENABLES EARLY IDENTIFICATION OF POTENT OMICRON-NEUTRALIZING ANTIBODIES

PRNewswire | June 14, 2023

PhenomeX Inc. the functional cell biology company, announced that the Company's technology was recently featured in a groundbreaking study published in Cell Reports titled "Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence" that has revealed the remarkable efficacy of vaccines in generating potent antibodies against emerging variants at an accelerated rate. The study, conducted by researchers from the La J...

Read More
news image

TARGOVAX PLANS CHECKPOINT COMBO TRIAL AFTER POSTING EARLY DATA ON ONCOLYTIC VIRUS

FierceBiotech | January 22, 2020

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the ...

Read More
news image

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More